In this expert discussion, Prof Gunhild von Amsberg (Martini-Klinik, Hamburg, Germany) and Prof Eva Compérat (Medical University of Vienna, Vienna, Austria) explore clinical decision-making for BRCA testing in prostate cancer and how to interpret next-generation sequencing (NGS) results.

They review the full molecular testing pathway for identifying BRCA1/2 alterations, including data analysis, reporting standards, and key considerations in interpreting results. The conversation also highlights the biological role of homologous recombination repair (HRR) and how its disruption can lead to tumour cell death, forming the basis for targeted therapies.

Clinical implications are discussed, including evidence that patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA alterations derive the greatest benefit from PARP inhibitor therapy. Key findings from the AMPLITUDE trial and its safety profile are also covered.

The discussion emphasises the importance of a multidisciplinary team approach to ensure accurate testing, interpretation, and optimal treatment decision-making in prostate cancer.

To watch the other videos in this series click here.